Clinical Trial Update: A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients [Phase 1]

View source ↗

Summary

A Phase 1 pilot trial evaluating sorafenib biomarkers in patients with refractory or relapsed T-cell lymphoma has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Yale University | Conditions: T Cell Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2020-08-13